Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2024

Year

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet‐Loiseau,

The Lancet Oncology

Hematological MalignancyMedicineDaratumumab MaintenanceHematologyMyeloid NeoplasiaMultiple MyelomaImmunotherapyOncologyRadiation OncologyPhase 3Health Sciences